Connect with us

Better Vision

Diabetic Retinopathy is Preventable Vision Loss with These Latest Tools and Treatments

The number of Americans suffering from diabetes-related blindness is expected to nearly double by 2050 but we have the means to help stop this silent killer of vision.

mm

Published

on

DIABETIC RETINOPATHY (DR) IS a leading cause of blindness in US adults. From 2010-50, the number of Americans with DR is expected to nearly double from 7.7 million to 14.6 million. Diabetes can affect the eyes before changes are detectable, so patients may not know damage is occurring until their vision is threatened. This year, a study by Elsevier for the American Academy of Ophthalmology found a delay in care of just 5.34 weeks in patients requiring intravitreal injections resulted in vision loss. To raise awareness of the link between diabetes and eye health, Regeneron has sponsored a national educational campaign (noweyesee.com) and RETINA-AI Health has just submitted its Galaxy autonomous screening device for DR to the FDA for clearance.

EyeArt AI Eye Screening System

Eyenuk

The EyeArt AI Eye Screening System is FDA-cleared artificial intelligence technology for autonomous detection of DR.

(818) 835-3585, meyenuk.co

Lucentis injection

Genentech

A Lucentis injection can treat all forms of DR in people with or without diabetic macular edema (DME).

(800) 626-3553, gene.com

biomarkers in four types of diabetic eyes

Indiana University School of Optometry

Retinal research detects biomarkers in four types of diabetic eyes using specialized optical techniques. Clockwise from top left: Typical DME; significant pathological changes; retina with normal retinal thickness and minimal diabetic changes; traction, along with a detaching vitreous.

optometry.iu.edu

Advertisement

EYLEA injection

Regeneron Pharmaceuticals

An EYLEA injection every 16 weeks is designed to block the growth of new blood vessels in the eye and decrease the ability of fluid to pass through blood vessels.

(914) 847-7000, -eylea.us

Valeda Light Delivery System

LumiThera

The Valeda Light Delivery System studies the effects of the device in DME patients.

(844) 342-3333, lumithera.com

Ozurdex

Allergan

Ozurdex is a small implant that is injected directly into the back of the eye and slowly releases medication over time without the need for monthly injections.

(844) 639-2246, ozurdex.com

Smart Ways to Discuss Diabetic Retinopathy Treatments

Allen Ho, MDWills Eye Hospital, Philadelphia, PA

Ho_Allen

Diabetic Retinopathy can progress without symptoms and is the top cause of blindness in working age Americans. Only about half of those with known diabetes get an annual diabetic eye exam with a retina specialist. Our focus should be on communicating with frontline eyecare providers. If we can get to patients in time we can stabilize and reverse damage and sometimes improve vision. Retina specialists have the tools to prevent blindness in about 90% of patients. We can use new injectable medicines like Eylea, Lucentis, Avastin and Ozurdex, and laser and surgical treatments. In the future, AI will help detect who is at risk, say, a patient who is a smoker, obese, has high blood pressure, or lives a sedentary life. New therapies, like gene therapy, are being explored.

A. Paul Chous, ODChous Eye Care Associates, Tacoma, WA

paul-chous

Caring for patients with diabetes is a mainstay of my practice. I try to prevent or delay the development of nonproliferative diabetic retinopathy with good, early metabolic control. Unfortunately, we’re doing a lousy job of getting early, good control in many patients. Once the “horse is out of the barn” and they have moderately severe or worse nonproliferative DR, improved metabolic control has limited effect on outcomes. Then I’ll send them to a retina specialist to see if they may benefit from anti-VEGF therapy. Hopefully, I can introduce them early enough to build rapport before they need invasive treatments like intravitreal injections. Use of red-free and ultrawide-field imaging, along with optical coherence tomography for DME and OCTA for subclinical retinopathy, can help us more accurately detect DR severity. Artificial Intelligence systems available from EyeNuk and others can assist with more accurate grading. Along with patient education and conventional imaging, they may help patients fully appreciate the severity of their condition.

 

Carol Gilhawley is a contributing writer for INVISION.

SPONSORED VIDEO

See What’s Possible with EssilorLuxottica 360

When you have 360 degrees of support, you can grow your independent practice with confidence. When that support comes from industry leaders with a proven track record of providing partnership opportunities which help independent practices maximize their success – well, the possibilities are endless. From increased visibility through cutting-edge marketing to enhanced patient experiences leading to a better capture rate and everything in between, see what’s possible with EssilorLuxottica 360. Learn more at 360.EssilorLuxottica.com. Powering your practice. Empowering you.

Promoted Headlines

Advertisement

Advertisement

Subscribe

INVISIONMAG.COM
BULLETINS

Get the most important news and business ideas for eyecare professionals every weekday from INVISION.

Advertisement

Most Popular